Tokyo Medical and Dental University Graduate School
Department of Immunotherapeutics
2018擭8寧31擔乣9寧2擔丂戞5夞擔杮HTLV-1妛夛妛弍廤夛傪庡嵜 偟傑偟偨
嫵 庼丂恄撧栘 恀棟
仹113-8519 搶嫗搒暥嫗嬫搾搰1挌栚5斣45崋
搶嫗堛壢帟壢戝妛 M&D僞儚乕17F
戝妛堾堛帟妛憤崌尋媶壢 惗懱娐嫬墳摎妛宯
姶愼墳摎妛島嵗 柶塽帯椕妛暘栰
TEL: 03-5803-5798
FAX: 03-5803-0235
丂僂僀儖僗偺帩懕姶愼偱惗偠傞埆 惈庮釃丒柶塽晄慡丒帺屓柶塽丒墛徢摍偺懡嵤側昦懺偵偼屄懱偺柶塽 墳摎偑戝偒偔塭嬁偡傞丅杮島嵗偱偼丄偙偺昦懺敪惗婡彉偲柶塽偺偐偐傢傝傪夝柧偟丄幘姵偺棟夝偵 偲偳傑傜偢丄幘姵偺夝寛傪栚巜偡柶塽帯椕曽朄偺壜擻惈傪捛媮偡傞丅暘栰偲偟偰偼丄柶塽妛丒 僂僀 儖僗妛丒暘巕惗暔妛偵傑偨偑傝丄婎慴偲椪彴偺拞娫偵埵抲偡傞丅
丂 僸僩T嵶朎敀寣昦僂僀儖僗1宆 乮HTLV-I丄human T-cell leukemia virus type I/human T-lymphotropic virus type 1乯偼丄寣塼庮釃惈幘姵偱偁傞惉恖T嵶朎敀寣昦乮ATL丄adult T-cell leukemia/lymphoma乯丄恄宱偺墛徢惈扙悘幘姵偱偁傞HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis)丄偦偺懠偺幘姵傪堷偒婲偙偡丅偙偺傛偆側懡嵤側昦懺偼僂僀儖僗偦偺傕偺偺昦尨惈偩偗偱愢柧偟摼傞傕偺偱偼側偔丄廻庡偺柶塽墳摎偑 枾愙偵娭傢偭偰偄傞丅変乆偼偙傟傑偱偵丄椪彴専懱傗摦暔儌僨儖傪梡偄偨夝愅偱丄HTLV- 1偵懳偡傞嵶朎彎奞惈T嵶 朎(CTL)墳摎偑ATL偱偼尭庛丄HAM/TSP偱偼槾恑偟偰偄傞偙偲(38, 45, 46)丄CTL偺庡梫昗揑峈尨Tax傪昗揑偲偟偨儚僋僠儞偑峈庮釃岠壥傪帩偮偙偲傪棫徹偟 偨(10, 12-15)丅偝傜偵丄憿寣姴嵶朎堏怉屻偵姲夝偟偨ATL姵幰偺堦晹偱Tax摿堎揑CTL墳摎 偑妶惈壔偡傞尰徾傪尒偄偩偟丄CTL偑擣幆偡傞Tax抈敀撪偺庡梫側僄僺僩乕僾偺傾儈僲攝 楍傪 摨掕偟偨乮19, 29乯丅偙傟傜偺僄僺僩乕僾偼擔杮恖偵懡偄HLA-A24, A2, A11偺偦傟偧傟偵懳墳偡傞CTL偺庡梫擣幆僄僺僩乕僾偱偁傞偨傔丄婛偵CTL偺専弌媄弍偵幚梡壔偝傟丄峈庮釃儚僋僠儞峈尨偲偟偰傕桳梡偱偁傞丅
丂変乆偼傑偨丄姶愼宱楬偲廻庡柶塽偺娭學偵偮偄偰傕夝愅傪峴偄丄曣擕姶愼偺傛偆側宱岥姶愼 偱偼丄 HTLV-1偵懳偡傞柶塽姲梕偑惉棫偟僾儘僂僀儖僗検偺憹壛傪嫋偡偙偲傪摦暔儌僨儖偱帵偟丄塽 妛揑側ATL婋尟場巕偱偁傞悅捈姶愼偲崅僾儘僂僀儖僗検偺娭學偵柶塽妛揑崻嫆傪梌偊偨 乮17丆33乯丅偙傟傜偺尋媶惉壥偼丄廻庡偺HTLV-1摿堎揑側T嵶朎墳摎偑丄HTLV-1姶愼偵傛傞敪娻偺梷巭椡偲側偭偰偍傝丄姶愼宱楬偦偺懠偺梫場 偱掅壓偟偨HTLV-1摿堎揑T嵶 朎墳摎傪妶惈壔偝偣傞偙偲偵傛傝ATL偺儕僗僋傪寉尭偱偒傞壜擻惈傪帵偟偰偄傞乮57乯丅
偙傟傑偱偺婎慴尋媶惉壥偵婎偯偒丄峈ATL柶 塽椕朄乮峈庮釃儚僋僠儞乯偲偟偰丄Tax摿 堎揑CTL僄僺僩乕僾晹埵偺儁僾僠 僪傪揧壛偟偨帺壠庽忬嵶朎儚僋僠儞傪奐敪偟偨乮54乯丅 尰嵼丄嬨廈偑傫僙儞僞乕偲偺嫟摨偱丄壔妛椕朄屻偺ATL姵 幰偵懳偟偰Tax儁僾僠僪揧壛庽忬 嵶朎儚僋僠儞椕朄偺椪彴帋尡巤峴偟偰偍傝丄僷僀儘僢僩僗僞僨傿偱偼3椺拞2椺偑4擭埲忋惗 懚丄懕偔戞I憡帋尡偵偍偄偰傕椙岲 側宱夁偑摼傜傟偰偄傞乮54, 60乯丅崱屻偝傜偵偙傟傪 敪揥偝偣丄敪徢梊杊傪帇栰偵偄傟偨儚僋僠儞奐敪傪栚巜偟偨偄丅
丂偙傟傜偺妉摼柶塽偺尋媶偲暯峴偟偰丄挿擭枹夝柧偱偁偭偨惗懱 撪偱偺HTLV-1敪尰梷惂婡彉丄 AZT-IFN兛帯椕偺嶌梡婡彉丄ATL嵶朎偺峆忢揑NF內B妶惈壔婡彉 偵娭偟偰帺慠柶塽偺 娭梌傪帵偡愭嬱揑側抦尒傪摼偨乮2, 11, 50, 53乯丅 偙傟偼丄偙傟傑偱怣偠傜傟偰偒偨惗懱撪偺HTLV-1堚揱巕敪尰偵 偮偄偰偺奣擮傪懪偪攋傞傕偺偱偁傞丅偝傜偵丄僂僀儖 僗懁偵偼幘姵摿堎揑側堘偄偑柍偄偵傕峉傜偢丄HTLV-1偑 庮釃惈幘姵偱偁傞ATL偲 墛徢惈幘姵偱偁傞HAM/TSP傪 堷偒婲偙偡婡彉傕挿擭偺撲偱偁偭偨偑丄変乆偼IL10-STAT3-IRF4僔 僌僫儖宱楬偑庮釃壔偺僗僀僢僠偲側偭偰偄傞偙偲傪尒偄偩偟丄廻庡柶塽偵傛 傞旝彫娐嫬偑幘姵敪尰偵廳梫側栶妱傪扴偆偙偲傪帵偟偨乮59乯丅偙傟傜堦楢偺敪尒 偼丄廻庡偺妉摼柶 塽偵壛偊偰帺慠柶塽偑 HTLV-1姶愼嵶朎偺僐儞僩儘乕儖偵娭傢傝嶰偮 攂偺娭學偵偁傞偙偲傪帵偟偰偄傞丅
丂傑偨丄AIDS乮acquired immunodeficiency syndrome乯偺尨場僂僀儖僗丄僸僩柶塽晄慡僂僀儖僗乮HIV-1丄human immunodeficiency virus type 1乯偵娭偡傞尋媶偱偼丄憹揷弝嫵庼偑HIV-1偺integrase偑僂僀儖僗堚揱巕偺慻傒崬傒抜奒偩偗偱側偔媡揮幨傗妀撪桝憲抜奒偵傕昁恵偺栶妱傪壥偨 偡偙偲傪尒偄偩偟乮11, 26乯偦偺妶惈晹埵偍傛傃廻庡懁場巕偱偁傞Gemin2/SIP1傪摨掕偟偨乮32, 34, 42, 47乯丅偙傟傜偼怴偨側峈HIV-1帯椕栻偺奐敪偵帒偡傞傕偺偱偁傞丅偙傟傜偺桳梡側尋媶偺懡偔偼 戝妛堾惗偑尋媶偺扴偄庤偲偟偰曇傒忋偘偰偒偨傕偺偱偁傝丄崱屻傕桪廏側戝妛堾 惗偺尋媶嶲壛 傪婜懸偡傞丅
仠 惉恖T嵶朎敀寣昦乮ATL乯偺敪徢梊杊丒帯椕傪栚揑偲偡傞柶塽椕朄乮峈庮釃儚僋僠 儞乯偺奐敪
仠 HTLV-1姶愼偵傛傞幘姵偺敪徢婡彉偲敪徢儕僗僋偵娭偡傞尋媶
仠 僂僀儖僗帩懕姶愼偵偍偗傞帺慠柶塽偺栶妱偵娭偡傞尋媶
仠 HIV-1僀儞僥僌儔乕僛傪拞怱偲偡傞HIV暋惢偺暘巕婡峔偺尋媶
仠 HIV-1姶愼杊屼偍傛傃HIV暋惢梷惂偵娭偡傞柶塽尋媶
亂 偙傟傑偱偺尋媶惉壥/嬈愌 亃
(1) ATL偵懳偡傞庮釃儚僋僠儞椕朄 亀ATL偵懳偡傞Tax摿堎揑T嵶朎墳摎晩妶壔儁僾僠僪僷儖僗庽忬嵶朎傪梡偄偨怴婯柶塽椕朄亁偺戞I憡椪彴帋尡傪奐巒偟傑偟偨丅
Suehiro, Y., Hasegawa, A., et al. Br J Haematol. 169(3):356-67, 2015.
Kannagi, M., Hasegawa, A., et al. Cancer Sci. 2019. in press.
偙傟傑偱拁愊偟偰偒偨柶塽尋媶惉壥傪摜傑偊丄搶嫗堛壢帟壢戝 妛丄嬨廈偑傫僙儞僞乕丄嬨廈戝妛娫偺嫟摨尋媶偱丄ATL偵懳偡傞柶塽椕朄乮庮釃儚僋僠儞乯傪奐敪偟丄2012擭偐傜 椪彴帋尡傪奐巒偟偨丅杮椪彴帋尡偼丄懱奜偱惉弉偝偣偨姵幰帺恎偺庽忬嵶朎偵丄HTLV-1 Tax偺僆儕僑儁僾僠僪傪峈尨偲偟偰揧壛偟儚僋僠儞愙庬偡傞傕偺偱偁傞丅巊梡儁僾僠僪偺傾儈僲巁攝楍偼丄変乆偑摨掕偟偨HTLV-1 Tax摿堎揑CD8梲惈嵶朎彎奞惈T嵶朎乮CTL乯偺庡梫昗揑僄僺僩乕僾 攝楍偱偁傝丄HLA-A2, HLA-A24, HLA-A11偺偄偢傟偐傪帩偮徢椺偵揔墳壜擻偱偁傞丅乮椪彴帋尡杮晹丗嬨廈偑傫僙儞僞乕 寣塼撪壢丄帋尡幚巤婡娭丗搶嫗堛壢帟壢戝妛 柶塽帯椕妛暘栰丄寣塼撪壢丄嬨廈戝妛 堚揱巕嵶朎帯椕晹乯丅
乮2乯 Tax儁 僾僠僪僷儖僗庽忬嵶朎儚僋僠儞偑丄HTLV-1宱岥姶愼儌僨儖偵偍偄偰HTLV-1僾 儘僂僀儖僗検傪掅壓偝偣傞偙偲傪棫徹偟傑偟偨丅
Ando S.,
Hasegawa A., et al. J Immunol.
198(3):1210-1219, 2017. 乮妛埵榑暥乯
乮3乯 峈墛徢惈僒僀僩僇僀儞IL-10偲偦偺壓棳偺STAT3-IRF4偺宱楬偺妶惈壔偑丄HTLV-1 姶愼偵偍偄偰庮釃壔傊偺僗 僀僢僠偲側偭偰偄傞偙偲傪弶傔偰柧 傜偐偵偟傑偟偨丅
Sawada L, Nagano Y., et al. PLoS Pathog. 13(9):e1006597, 2017. 乮妛埵榑暥乯
HAM乮墛徢惈幘姵乯姵幰桼棃偺HTLV-1姶愼嵶朎姅偵IL-10僔僌僫儖偑壛傢傞偲憹怋惈 偵揮偠丄STAT3, IRF4偺 妶惈壔傪夘偟偰ATL嵶 朎乮庮釃惈幘姵乯偺摿挜揑側宍幙傪妉摼偡傞偙偲偑暘偐偭偨丅HTLV-1 姶愼偵偍偄偰丄僂僀儖僗懁 偵堘偄偑柍偄偵傕峉傜偢慡偔堎側傞庮釃惈幘姵偲墛徢惈幘姵偑婲偙傞婡彉偼挿傜偔晄 柧偱偁偭偨偑丄嵶朎奜旝彫娐嫬偵傛偭偰幘姵偺曽岦惈偑曄傢傞壜擻惈傪帵偟偨嵟弶偺榑暥 偱偁傞丅
乮4乯 HTLV-1 Tax摿堎揑CD4梲惈僿儖僷乕T嵶朎偺怴婯昗揑僄僺僩乕僾傪摨掕偟丄偙傟偑CD8梲惈CTL偺妶惈壔岠棪傪憹嫮偡傞偙偲傪柧傜偐偵偟傑偟偨丅
Tamai Y., Hasegawa A., et al. J Immunol. 190(8):4382-92, 2013.丂乮妛埵榑暥乯
憿寣姴嵶朎堏怉屻偵姲夝偟偨ATL徢椺偐傜丄崱夞偼偠傔偰HTLV-1摿堎揑 CD4梲惈僿儖僷乕T嵶朎偺庽棫偵惉岟偟丄偦偺昗揑峈尨偑傗偼傝HTLV-1 Tax偱偁偭偨偙偲偑暘偐傝丄徻嵶側夝愅偺寢壥丄HLA-DR1偵峉懇偝傟傞 庡梫擣幆僄僺僩乕僾乮13傾儈僲巁乯傪摨掕偟偨丅廳梫側偙偲偵丄偙偺僿儖僷乕 僄僺僩乕僾偼CD8梲惈Tax摿堎揑CTL偺桿摫岠棪傪奿抜偵憹壛偝偣偨丅崱 屻丄僥僩儔儅乕偵傛傞僿儖僷乕T嵶朎偺摨掕傗丄儚僋僠儞傊偺墳梡偑婜懸偝傟 傞丅
乮5乯 ATL徢椺偲堦晹偺柍徢岓HTLV-1僉儍儕傾偱丄HTLV-I摿堎揑側T嵶朎墳摎晄慡偑偁傞偙偲偑暘偐傝傑偟偨丅
Takamori A., Hasegawa A., et al. Retrovirology. 8:100, 2011.丂 乮妛埵榑暥乯
Shimizu Y., et al. Cancer Sci. 100: 3, 481-489, 2009. 乮妛埵榑暥乯
Kannagi M., et al. Frontiers Microbiol. 3:323, 2012.
枹帯椕偺枬惈ATL姵幰偱偼HTLV-1 Tax摿堎揑CTL偺専弌昿搙偑掅偔墳摎惈傕朢偟偄偑丄柍徢岓HTLV-1姶愼幰偺87亾偱偼HTLV-1 Tax摿堎揑CTL偑専弌偝傟偨丅偟偐偟丄柍徢岓幰偺拞偵傕Tax摿堎揑 CTL偑専弌偝傟側偄椺傗丄専弌偝傟偰傕墳摎晄慡傪帵偡椺偑彮悢偁傝丄堦曽僒 僀僩儊僈儘僂僀儖僗偵懳偡傞墳摎惈偼曐偨傟偰偄偨丅埲忋偐傜丄柍徢岓婜偵傕堦 晹偺姶愼幰偱偼峈HTLV-1墳摎偑慖戰揑偵梷惂 偝傟偰偍傝丄ATL偺儕僗僋梫場偲側傞壜擻惈偑帵嵈偝傟偨丅
乮6乯 塱擭偺撲偱偁偭偨惗懱撪偺HTLV-I堚 揱巕敪尰梷惂婡彉丄AZT/IFN兛椕朄偺嶌梡婡彉丄ATL嵶朎偺峆忢揑NF內B妶惈壔婡彉傊偺帺慠柶塽偺娭梌傪弶傔偰巜揈偟傑偟偨丅
Kinpara, S., et al. Leukemia.
29(6):1425-1429, 2015.
Kinpara,
S., et al. Retrovirology.
10: 52, 2013.
Kannagi M., et al. Cancer Sci. 102丗670-676, 2011.
枛徑寣偐傜暘棧捈屻偺ATL嵶朎偵偼HTLV-1抈敀偼専弌偝傟偢丄悢帪娫偺攟梴屻媫寖偵敪尰偡傞尰徾偑抦傜傟偰偄傞偑丄偦偺婡 彉偼挿傜偔晄柧偱偁偭偨丅 変乆偼丄HTLV-1姶愼嵶朎傪忋旂嵶朎偲嫟攟梴偡傞偲僂僀儖僗敪尰偑梷惂偝 傟丄偙傟偑I宆僀儞僞乕僼僃儘儞傪夘偡傞偙偲傪尒偄偩偟偨丅 偙偺強尒傪婎 偵丄AZT/IFN兛偺暪 梡偑Tax抈 敀偺東栿梷惂偲p53妶 惈壔傪桿摫偡傞偙偲丄偝傜偵丄ATL嵶 朎偺Tax旕 埶懚惈偺NFkB妶 惈壔偵PKR偑娭梌偡傞偙偲傪曬崘偟偨丅
乮7乯 憿寣姴嵶朎堏怉屻偺ATL姵幰偱HTLV-1 Tax摿堎揑嵶朎彎奞惈T嵶朎乮CTL乯偑妶惈壔偡傞偙偲傪尒弌偟丄HLA-A2, A24, A11偵峉懇偝傟傞CTL偺儊僕儍乕僄僺僩乕僾傪摨掕偟傑偟偨丅
Harashima N., et al. Cancer Res. 64(1):391-399, 2004.
Harashima N., et al. J Virol. 79(15):10088-10092, 2005.
Kannagi M., et al. Trends Microbiol. 12(7):301-352, 2004.
旕姶愼幰桼棃偺憿寣姴嵶朎堏怉弍傪庴偗姲夝偟偨ATL姵幰偐傜丄堏怉慜偺帺屓HTLV-1姶愼嵶朎偵懳偡傞CTL偺憹壛傪擣 傔丄偙傟傜偑Tax摿堎揑CTL偱偁傞偙偲傪尒偄偩偟偨丅偙傟傜偺CTL偺夝愅偐傜丄擔杮恖偵懡偄HLA-A24, A2, A11偵峉懇偝傟傞庡梫側CTL僄僺僩乕僾傪摨掕偟偨丅偙傟偵傛傝丄枛徑寣偐傜捈愙CTL傪専弌偡傞専嵏偑偱偒傞傛偆偵側偭 偨丅
乮8乯ATL偺摦暔儌僨儖傪庽棫偟丄Tax傪昗揑偲偡傞DNA儚僋僠儞偍傛傃CTL僄僺僩乕僾 晹埵偺儁僾僠僪儚僋僠儞偑峈庮釃岠壥傪帩偮偙偲傪幚 徹偟傑偟偨丅
Hanabuchi S., et al. J. Natl. Cancer Inst. 93(23):1775-1783, 2001.
Hanabuchi S., et al. J. Virol. 74(1):428-435, 2000.
Ohashi T., et al. J. Virol. 74(20):9610-9616, 2000.
Ohashi T., et al. J. Virol. 73(7):6031-6040, 1999.
Kannagi M., et al. Cancer Sci. 96(5):249-255, 2005.
乮9乯 HTLV-1帩懕姶愼屄懱偵懳偡傞嵞柶塽偑丄HTLV-1摿堎揑T嵶朎墳摎傪夞暅偝偣丄惗 懱撪僾儘僂僀儖僗検傪尭彮偝偣傞偙偲傪摦暔幚尡偱徹柧偟傑偟 偨丅
Komori K., Hasegawa, A., et al. J. Virol. 80(15):7375-7381, 2006. 乮妛埵榑暥乯
乮10乯丂HTLV-1宱岥姶愼偱偼丄HTLV-1摿堎揑T嵶朎墳摎偑掅偔 惗懱撪僾儘僂僀儖僗検偼憹壛偡傞偙偲傪帵偟傑偟偨丅偙傟偵傛傝曣巕姶愼 偑ATL婋尟場巕偺堦偮偱偁傞偲偄偆塽妛揑強尒傪柶塽妛揑偵棤晅偗傑偟 偨丅
Hasegawa A., et al. J. Virol. 77(5):2956-2963, 2003. 乮妛埵榑暥乯
Kato H., et al. J. Virol. 72(9):7289-7293, 1998.
乮1乯 HIV-1偺僀儞僥僌儔乕僛偼僂僀儖僗棻巕宍惉傗媡揮幨儗儀儖偵廳梫側栶妱傪 偟偰偄傞偑丄偙偺枹抦婡擻敪婗偵昁恵側傾儈僲巁巆婎偲怴婯慜嬱懱抈敀幙峔憿傪採帵偟傑偟偨丅
Takahata T., et al. J Virol. 91(1) pii: e02003-16, 2017.乮妛埵榑暥乯
乮2乯 HIV-1偺mRNA偺 偆偪揮幨奐巒晹埵偺G墫婎偑侾屄偺揮幨嶻暔偑慖 戰揑偵僂僀儖僗棻巕撪偵庢傝崬傑傟丄媡揮幨斀墳偺悑峴偵傕廳梫側栶妱傪壥偨偡偙偲傪尒偄偩偟傑偟偨丅
Masuda T., et al. Sci Rep. 5:17680, 2015.
乮3乯 HIV-1偺僀儞 僥僌儔乕僛偑廻庡場巕SIP1/Gemin2偲夛崌偟丄僂僀儖僗偺媡揮幨岠棪傪憹壛偝偣傞偙偲傪尒偄偩偟傑偟偨丅
Nishitsuji H., et al. PLoS One 4:e7825. 2009. 乮妛埵榑暥乯
Masuda T., Frontiers Microbiol. 2, 210, 2011.
乽慻傒崬傒乿夁掱偺怗攠峺慺偱偁傞僀儞僥僌儔乕僛偲偦偺寢崌場巕偲偟偰変乆偑摨掕 偟偨廻庡場巕乮Gemin2乯偼丄媡揮幨暋崌懱偺埨掕壔傪懀恑偟丄HIV堚揱巕偺 乽媡揮幨乿夁掱懀恑偵昁梫偱偁傞偙偲傪帵偟偨丅杮婡擻偼丄峈HIV嵻奐敪偵偍偗 傞丄僀儞僥僌儔乕僛偺怴婯昗揑偲側傝偆傞傕偺偲峫偊傜傟偨丅
乮4乯 TLR4傪慖戰揑偵巋寖偡傞忢嵼嬠偼丄I宆僀儞僞乕僼僃儘儞墳摎傪夘偟偰儅僋儘僼傽乕僕 偺HIV-1暋惢傪梷惂偡傞偙偲偑暘偐傝傑偟偨丅
Ahmed N., et al. J Gen Virol., 91: 2804-2813, 2010. 乮妛埵榑暥乯
HIV-1姶愼偵懳偟偰掞峈惈傪晅梌偡傞惗懱撪娐嫬偺岓曗偲偟偰忢嵼嬠傪憐掕 偟丄庬乆偺忢嵼嬠偺儅僋儘僼傽乕僕偵偍偗傞HIV-1暋惢傊偺塭嬁傪専摙偟 偨丅偦偺寢壥丄HIV-1暋惢傪梷惂偡傞忢嵼嬠偼TLR4傪慖戰揑偵巋寖偟I 宆僀儞僞乕僼僃儘儞傪桿摫偡傞偑丄偦傟埲奜偼TLR2巋寖岠壥傪帩偮嬠偱偁傞 偙偲偑暘偐偭偨丅
乮5乯 HIV-侾僀儞僥僌儗乕僗偺婡擻偵昁恵側傾儈僲巁巆婎偺峔憿傊偺塭嬁傪摿掕偟傑偟偨丅偙傟偼怴偨側峈HIV嵻偺昗揑峈尨偲埵抲偯偗傜傟傑偡丅
Nomura Y, et al. J Biochem. 139: 753-9, 2006.
Masuda T., Frontiers Microbiol. 2: 210, 2010.
乮6乯 HIV-1僀儞僥僌儗乕僗偵寢崌偟妿偮HIV-1暋惢偵昁梫側廻庡場巕傪摨掕偟傑偟偨丅
Hamamoto, S, et al. J Virol. 80: 5670-5677, 2006. 乮妛埵榑暥乯
乮7乯 HIV-1偺暋惢梷惂偵岠壥揑側shRNA偺昗揑攝楍傪僀儞僥僌儔乕僛撪偵尒弌偟傑偟偨丅
Nishitsuji, H, et al. J Virol. 80: 7658-66, 2006. 乮妛埵榑暥乯
Nishitsuji, H, et al. Microb. Infect. 6: 76-85, 2004. 乮妛埵榑暥乯
乮8乯 HIV-1僀儞僥僌儗乕僗偑僂僀儖僗慻傒崬傒埲奜偵傕暋悢偺儗 儀儖偱僂僀儖僗暋惢偵昁恵偺栶妱傪壥偨偡偙偲傪柧傜偐偵偟傑偟偨丅
Masuda T., et al. J Virol. 69: 6687-96, 1995.
Tsurutani N., et al. J Virol. 74:795-806, 2000. 乮妛埵榑暥乯
Ikeda T., et al. J Virol. 78:11563-73, 2004. 乮妛埵榑暥乯
乮9乯 CD8梲惈CTL偼丄壜梟惈場巕偱偼側偔嵶朎愙怗偵傛傝HIV-1憹怋傪梷惂偟丄偙偺梷惂偵峈尨摿堎惈偼昁恵偱側偄偙偲傪帵偟傑偟偨丅
Liu H., et al. Viral Immunol. 16(3):381-393, 2003. 乮妛埵榑暥乯
Ohashi T., et al. J Gen Virol. 80:209-216, 1999.
Kubo M., et al. J Virol. 71(10):7560-7566, 1997. 乮妛埵榑暥乯
(1) SARS-CoV摿桳偺抈敀偺偆偪2庬椶偺傾僋僙僒儕乕抈敀乮X1, X3乯偑嫮偄NF內B妶惈壔擻傪帩偪墛徢惈働儌僇僀 儞傪桿摫偡傞偙偲傪尒弌偟傑偟偨丅
Kanzawa N., et al. FEBS letters. 580(30):6807-6812, 2006. 乮妛埵榑暥乯
Obitsu S, et al. Arch. Virol. 154(9):1457-1464, 2009. 乮妛埵榑暥乯
搶
嫗堛壢帟壢戝妛儂乕儉儁乕僕傊栠傞丂 丂丂丂
戝妛堾堛帟妛憤崌尋媶壢偺儁乕僕傊栠傞
偙 偺 儂乕儉儁乕僕偺偍栤偄崌傢偣偼
偵偍婅偄偄偨偟傑偡丅